Liu Min, Mao Chenhan, Zhao Fusen, Chen Zhaoyang, Wang Xindong
The Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China.
Front Cardiovasc Med. 2023 Aug 7;10:1229021. doi: 10.3389/fcvm.2023.1229021. eCollection 2023.
Upstream treatment of atrial fibrillation (AF, for short) is a new approach to the prevention and treatment of AF with non-antiarrhythmic drugs, which is essentially primary and secondary prevention of AF. The former refers to the prevention of AF by controlling risk factors such as diabetes, hypertension, and heart failure before AF occurs, and the latter mainly refers to targeting ion channels, inflammation, oxidative stress, and other pathways to reduce or reverse atrial electrical and structural remodeling, reduction of AF load, and reduction of the chance of AF occurrence or progression. More and more studies have shown that many traditional Chinese medicines, active ingredients of Chinese medicines, and Chinese herbal formulas have definite effects on the upstream treatment of AF, but their mechanisms of action are different. Therefore, we summarized the relevant literature on the application and mechanisms of Chinese medicine on the upstream treatment of AF in recent years, hoping to be helpful for subsequent studies.
房颤的上游治疗是一种使用非抗心律失常药物预防和治疗房颤的新方法,本质上属于房颤的一级和二级预防。前者是指在房颤发生前通过控制糖尿病、高血压和心力衰竭等危险因素来预防房颤,后者主要是针对离子通道、炎症、氧化应激等途径,以减少或逆转心房电重构和结构重构,降低房颤负荷,减少房颤发生或进展的几率。越来越多的研究表明,许多中药、中药活性成分和中药复方在房颤的上游治疗中具有确切疗效,但其作用机制各不相同。因此,我们总结了近年来中药在房颤上游治疗中的应用及作用机制的相关文献,希望对后续研究有所帮助。